ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
anemia |
J:134301
|
|
cachexia |
J:134301
|
|
increased gastrointestinal tumor incidence |
J:134301
|
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL
|
decreased tumor incidence |
J:134301
|
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
abnormal DNA methylation |
J:127808
|
|
increased intestinal adenoma incidence |
J:127808
|
|
increased tumor growth/size |
J:127808
|
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
increased colon tumor incidence |
J:231166
|
Atg5tm1.1Myok/Atg5tm1.1Myok
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal cell physiology |
J:205532
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
involves: 129S4/SvJae * BALB/c * C57BL/6
|
increased lung adenocarcinoma incidence |
J:235747
|
Col1a1tm1(CAG-Ezh2*)Meln/Col1a1+
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
normal
immune system phenotype |
J:199122
|
|
increased germinal center B cell number |
J:199122
|
|
increased spleen germinal center number |
J:199122
|
|
increased spleen germinal center size |
J:199122
|
|
normal
neoplasm |
J:199122
|
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp
Tg(Mx1-cre)1Cgn/0
Not Specified
|
abnormal erythropoiesis |
J:199366
|
|
abnormal hematopoietic system morphology/development |
J:199366
|
|
anemia |
J:199366
|
|
decreased leukocyte cell number |
J:199366
|
|
enlarged spleen |
J:199366
|
|
increased hematopoietic stem cell number |
J:199366
|
|
increased leukemia incidence |
J:199366
|
|
increased myeloid dendritic cell number |
J:199366
|
|
increased T cell derived lymphoma incidence |
J:199366
|
Col1a1tm1(CAG-Sirt2)Jmi/Col1a1+
Tg(Mpz-cre)26Mes/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal myelination |
J:177468
|
|
abnormal response to injury |
J:177468
|
Col1a1tm1(hs1473-PITX1)Smun/Col1a1+
involves: 129S4/SvJae * C57BL/6
|
abnormal digit morphology |
J:203670
|
|
abnormal forelimb morphology |
J:203670
|
|
abnormal forelimb zeugopod morphology |
J:203670
|
|
abnormal humerus morphology |
J:203670
|
|
fused carpal bones |
J:203670
|
|
oligodactyly |
J:203670
|
|
syndactyly |
J:203670
|
Col1a1tm1(tetO-CDKN2A)Ibp/Col1a1+
Tg(KRT5-rtTA)#Glk/0
involves: 129S4/SvJae * C57BL/6 * FVB
|
abnormal hair cycle |
J:196969
|
|
abnormal hair follicle development |
J:196969
|
|
abnormal skin physiology |
J:196969
|
|
alopecia |
J:196969
|
|
decreased hair follicle number |
J:196969
|
|
early cellular replicative senescence |
J:196969
|
|
thick epidermis |
J:196969
|
Col1a1tm1(tetO-CDKN2A)Ibp/Col1a1tm2(tetO-GFP/RNAi:Trp53)Slowe
Tg(KRT5-rtTA)#Glk/0
involves: 129S4/SvJae * C57BL/6 * FVB
|
normal
cellular phenotype |
J:196969
|
|
normal
integument phenotype |
J:196969
|
Col1a1tm1(tetO-cre)Haho/?
Gfi1btm1.1Haho/Gfi1btm1.1Haho
involves: 129S4/SvJaeSor * C57BL/6
|
abnormal megakaryocyte differentiation |
J:207446
|
|
abnormal megakaryocyte progenitor cell morphology |
J:207446
|
|
absent erythroid progenitor cell |
J:207446
|
|
absent platelets |
J:207446
|
|
anemia |
J:207446
|
|
decreased hemoglobin content |
J:207446
|
|
postnatal lethality, complete penetrance |
J:207446
|
|
thrombocytopenia |
J:207446
|
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
abnormal crypts of Lieberkuhn morphology |
J:193365
|
|
abnormal enterocyte apoptosis |
J:193365
|
|
abnormal enterocyte proliferation |
J:193365
|
|
abnormal intestine development |
J:193365
|
|
decreased body weight |
J:193365
|
|
normal
digestive/alimentary phenotype |
J:193365
|
|
increased enterocyte apoptosis |
J:193365
|
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal lymphatic vessel morphology |
J:206581
|
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
hepatic steatosis |
J:187378
|
|
increased circulating leptin level |
J:187378
|
|
increased liver weight |
J:187378
|
|
increased susceptibility to diet-induced obesity |
J:187378
|
|
increased triglyceride level |
J:187378
|
|
increased white adipose tissue amount |
J:187378
|
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129 * C57BL/6
|
abnormal tumor pathology |
J:166724
|
|
increased lung carcinoma incidence |
J:166724
|
|
increased lung tumor incidence |
J:166724
|
|
premature death |
J:166724
|
|
normal
respiratory system phenotype |
J:166724
|
|
weight loss |
J:166724
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
decreased fibroblast proliferation |
J:194505
|
|
increased sarcoma incidence |
J:194505
|
|
premature death |
J:194505
|
|
tumor regression |
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2
|
increased sarcoma incidence |
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
|
increased sarcoma incidence |
J:194505
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Rag1tm1Mom/Rag1tm1Mom
Tg(KRT5-rtTA)T2D6Sgkd/0
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
normal
integument phenotype |
J:201145
|
|
skin hyperplasia |
J:201145
|
|
skin lesions |
J:201145
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N
|
abnormal liver morphology |
J:210545
|
|
premature death |
J:210545
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
abnormal forestomach morphology |
J:201145
|
|
absent hair follicles |
J:201145
|
|
alopecia |
J:201145
|
|
decreased body size |
J:201145
|
|
epidermal hyperplasia |
J:201145
|
|
hyperkeratosis |
J:201145
|
|
normal
immune system phenotype |
J:201145
|
|
increased CD4-positive, alpha-beta T cell number |
J:201145
|
|
increased granulocyte number |
J:201145
|
|
increased incidence of tumors by chemical induction |
J:201145
|
|
increased keratinocyte proliferation |
J:201145
|
|
increased papilloma incidence |
J:201145
|
|
parakeratosis |
J:201145
|
|
premature death |
J:201145
|
|
skin hyperplasia |
J:201145
|
|
skin inflammation |
J:201145
|
|
skin lesions |
J:201145
|
|
thick skin |
J:201145
|
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Tg(Prkcd-glc-1/CFP,-cre)EH124Gsat/0
involves: C57BL/6J * FVB/NTac
|
abnormal cued conditioning behavior |
J:297390
|
|
decreased anxiety-related response |
J:297390
|
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Ssttm2.1(cre)Zjh/Sst+
involves: 129S4/SvJae * C57BL/6J
|
normal
behavior/neurological phenotype |
J:297390
|
|
impaired cued conditioning behavior |
J:297390
|
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:171191
|
Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell number |
J:229031
|
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
extramedullary hematopoiesis |
J:229031
|
|
increased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:203903
|
|
abnormal plasma cell differentiation |
J:203903
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4tm1Mak
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:203903
|
|
abnormal plasma cell differentiation |
J:203903
|
Col1a1tm1(tetO-Lin28a)Gqda/Col1a1+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
abnormal digestive system morphology |
J:166568
|
|
abnormal skeleton morphology |
J:166568
|
|
big ears |
J:166568
|
|
broad face |
J:166568
|
|
coarse hair |
J:166568
|
|
decreased circulating glucose level |
J:166568
|
|
decreased circulating insulin level |
J:166568
|
|
decreased susceptibility to age related obesity |
J:177113
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:177113
|
|
decreased susceptibility to diet-induced obesity |
J:177113
|
|
decreased total body fat amount |
J:177113
|
|
delayed female fertility |
J:166568
|
|
delayed sexual maturation |
J:166568
|
|
delayed vaginal opening |
J:166568
|
|
improved glucose tolerance |
J:166568,
J:177113
|
|
increased body length |
J:166568
|
|
increased body size |
J:166568
|
|
increased body weight |
J:166568
|
|
increased bone mineral content |
J:166568
|
|
increased bone mineral density |
J:166568
|
|
increased cell proliferation |
J:166568
|
|
increased growth rate |
J:166568
|
|
increased hepatocyte proliferation |
J:166568
|
|
increased insulin sensitivity |
J:166568,
J:177113
|
|
increased lean body mass |
J:177113
|
|
increased litter size |
J:166568
|
|
liver hyperplasia |
J:166568
|
|
premature death |
J:166568
|
|
normal
reproductive system phenotype |
J:166568
|
|
skin hyperplasia |
J:166568
|
|
small pancreatic islets |
J:166568
|
|
thick skin |
J:166568
|
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:179085
|
|
abnormal bone marrow cell physiology |
J:179085
|
|
abnormal proerythroblast morphology |
J:179085
|
|
decreased bone marrow cell number |
J:179085
|
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased megakaryocyte cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
normal
mortality/aging |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:179085
|
|
abnormal bone marrow cell physiology |
J:179085
|
|
abnormal large intestine morphology |
J:179085
|
|
abnormal proerythroblast morphology |
J:179085
|
|
decreased bone marrow cell number |
J:179085
|
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased megakaryocyte cell number |
J:179085
|
|
decreased neutrophil cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
premature death |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm1(tetO-SOX2)Mjm/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal ileum crypts of Lieberkuhn morphology |
J:199754
|
|
abnormal intestine physiology |
J:199754
|
|
ectopic Paneth cells |
J:199754
|
|
increased cell proliferation |
J:199754
|
Col1a1tm1(tetO-Stat1)Biat/Col1a1tm1(tetO-Stat1)Biat
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Stat1tm1Dlv/Stat1tm1Dlv
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
abnormal susceptibility to infection induced morbidity/mortality |
J:212694
|
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal circulating enzyme level |
J:174049
|
|
abnormal enterocyte proliferation |
J:174049
|
|
abnormal hepatocyte mitochondrial morphology |
J:174049
|
|
abnormal hepatocyte morphology |
J:174049
|
|
abnormal intestinal mucosa morphology |
J:174049
|
|
abnormal intestine development |
J:174049
|
|
abnormal pancreas physiology |
J:174049
|
|
abnormal small intestine morphology |
J:174049
|
|
decreased liver glycogen level |
J:174049
|
|
dehydration |
J:174049
|
|
normal
immune system phenotype |
J:174049
|
|
increased circulating alanine transaminase level |
J:174049
|
|
increased circulating alkaline phosphatase level |
J:174049
|
|
increased circulating amylase level |
J:174049
|
|
increased circulating aspartate transaminase level |
J:174049
|
|
increased circulating lactate dehydrogenase level |
J:174049
|
|
increased hepatocyte apoptosis |
J:174049
|
|
increased hepatocyte proliferation |
J:174049
|
|
lethargy |
J:174049
|
|
liver failure |
J:174049
|
|
microvesicular hepatic steatosis |
J:174049
|
|
premature death |
J:174049
|
|
weight loss |
J:174049
|
Col1a1tm1(tetO-U2AF1*S34F)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:221403
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
|
abnormal enzyme/coenzyme level |
J:217463
|
|
abnormal liver morphology |
J:217463
|
|
decreased circulating glucose level |
J:217463
|
|
increased bile salt level |
J:217463
|
|
increased circulating alanine transaminase level |
J:217463
|
|
increased circulating serum albumin level |
J:217463
|
|
increased hepatocellular carcinoma incidence |
J:217463
|
|
increased incidence of tumors by chemical induction |
J:217463
|
|
increased liver adenoma incidence |
J:217463
|
|
increased metastatic potential |
J:217463
|
|
liver failure |
J:217463
|
|
liver fibrosis |
J:217463
|
|
premature death |
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
|
decreased hepatocyte apoptosis |
J:217463
|
|
increased hepatocellular carcinoma incidence |
J:217463
|
|
premature death |
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1tm1(tetO-URI1)Ndj
Tg(Cebpb-tTA)#Bjd/0
B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
|
increased hepatocellular carcinoma incidence |
J:217463
|
Col1a1tm1(tetO-Vegfc)Mmul/Col1a1+
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:82809
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:222916
|
|
increased prostate gland tumor incidence |
J:222916
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
|
abnormal epidermal layer morphology |
J:171057
|
|
abnormal epidermal stem cell morphology |
J:171057
|
|
abnormal hair growth |
J:171057
|
|
abnormal tongue epithelium morphology |
J:171057
|
|
hyperkeratosis |
J:171057
|
|
increased cell proliferation |
J:171057
|
|
increased skin squamous cell carcinoma incidence |
J:171057
|
|
thick epidermis |
J:171057
|
|
thick skin |
J:171057
|
|
wrinkled skin |
J:171057
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal enterocyte proliferation |
J:141457
|
|
abnormal intestinal epithelium morphology |
J:141457
|
|
abnormal intestinal goblet cell morphology |
J:141457
|
|
absent Paneth cells |
J:141457
|
|
decreased alkaline phosphatase activity |
J:141457
|
|
enlarged pancreas |
J:141457
|
|
increased cell proliferation |
J:141457
|
|
increased pancreatic acinar cell number |
J:141457
|
|
pancreatic acinar-to-ductal metaplasia |
J:141457
|
|
premature death |
J:141457
|
|
thick skin |
J:141457
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
involves: 129S4/SvJae * C57BL/6
|
abnormal hepatocyte morphology |
J:141457
|
|
decreased hepatocyte apoptosis |
J:141457
|
|
enlarged liver |
J:141457
|
|
increased hepatocyte proliferation |
J:141457
|
|
increased liver weight |
J:141457
|
|
liver hyperplasia |
J:141457
|
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
premature death |
J:185310
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:194608
|
|
abnormal professional antigen presenting cell physiology |
J:194608
|
|
normal
immune system phenotype |
J:194608
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Tap1tm1Arp/Tap1tm1Arp
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
abnormal professional antigen presenting cell physiology |
J:194608
|
Col1a1tm2(CAG-IDH2*R172K)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6
|
abnormal mitochondrial crista morphology |
J:209629
|
|
abnormal mitochondrial morphology |
J:209629
|
|
abnormal mitochondrial physiology |
J:209629
|
|
abnormal myocardial fiber mitochondrial morphology |
J:209629
|
|
abnormal myocardial fiber morphology |
J:209629
|
|
abnormal sarcomere morphology |
J:209629
|
|
abnormal skeletal muscle fiber mitochondrial morphology |
J:209629
|
|
abnormal skeletal muscle morphology |
J:209629
|
|
abnormal Z line morphology |
J:209629
|
|
blood vessel congestion |
J:209629
|
|
brain vacuoles |
J:209629
|
|
cardiac fibrosis |
J:209629
|
|
decreased cardiac muscle contractility |
J:209629
|
|
decreased mitochondrial number |
J:209629
|
|
dilated cardiomyopathy |
J:209629
|
|
enlarged heart |
J:209629
|
|
increased cardiac muscle glycogen level |
J:209629
|
|
increased cardiomyocyte apoptosis |
J:209629
|
|
increased skeletal muscle glycogen level |
J:209629
|
|
lethargy |
J:209629
|
|
neurodegeneration |
J:209629
|
|
premature death |
J:209629
|
|
respiratory distress |
J:209629
|
|
skeletal muscle endomysial fibrosis |
J:209629
|
|
skeletal muscle fiber degeneration |
J:209629
|
|
skeletal muscle fiber necrosis |
J:209629
|
Col1a1tm2(tetO-CTNNB1*)Hoch/Col1a1tm2(tetO-CTNNB1*)Hoch
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal crypts of Lieberkuhn morphology |
J:191050
|
|
abnormal intestinal epithelium morphology |
J:191050
|
|
abnormal intestinal goblet cell morphology |
J:191050
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:191050
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:191050
|
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
decreased liver triglyceride level |
J:210545
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:210545
|
|
normal
homeostasis/metabolism phenotype |
J:213764
|
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S4/SvJae * C57BL/6 * CD-1
|
abnormal osteoblast morphology |
J:211215
|
|
abnormal osteoblast physiology |
J:211215
|
|
abnormal osteoclast morphology |
J:211215
|
|
normal
adipose tissue phenotype |
J:211215
|
|
decreased body weight |
J:211215
|
|
decreased circulating adiponectin level |
J:211215
|
|
decreased circulating glucose level |
J:211215
|
|
decreased circulating insulin level |
J:211215
|
|
decreased gonadal fat pad weight |
J:211215
|
|
decreased insulin secretion |
J:211215
|
|
improved glucose tolerance |
J:211215
|
|
increased bone ossification |
J:211215
|
|
increased bone trabecula number |
J:211215
|
|
increased bone volume |
J:211215
|
|
increased circulating osteocalcin level |
J:211215
|
|
increased insulin sensitivity |
J:211215
|
|
increased trabecular bone thickness |
J:211215
|
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell number |
J:229031
|
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
decreased hematopoietic stem cell number |
J:229031
|
|
enlarged spleen |
J:229031
|
|
extramedullary hematopoiesis |
J:229031
|
|
increased bone marrow cell number |
J:229031
|
|
increased granulocyte monocyte progenitor cell number |
J:229031
|
|
increased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
|
increased neutrophil cell number |
J:229031
|
|
increased spleen red pulp amount |
J:229031
|
|
myeloid hyperplasia |
J:229031
|
|
myeloid metaplasia |
J:229031
|
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal spleen morphology |
J:229031
|
|
anemia |
J:229031
|
|
decreased B cell number |
J:229031
|
|
enlarged spleen |
J:229031
|
|
myeloid hyperplasia |
J:229031
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129 * C57BL/6
|
increased leukemia incidence |
J:210097
|
|
premature death |
J:210097
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal hematopoietic stem cell proliferation |
J:210097
|
|
enlarged spleen |
J:210097
|
|
extramedullary hematopoiesis |
J:210097
|
|
normal
hematopoietic system phenotype |
J:210097
|
|
increased hematopoietic stem cell proliferation |
J:210097
|
|
increased leukemia incidence |
J:210097
|
|
normal
neoplasm |
J:210097
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * ICR
|
normal
renal/urinary system phenotype |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
abnormal kidney mesenchyme morphology |
J:211179
|
|
delayed kidney development |
J:211179
|
|
increased kidney tumor incidence |
J:211179
|
|
kidney cyst |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1
|
kidney cyst |
J:211179
|
|
normal
neoplasm |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
decreased susceptibility to diet-induced obesity |
J:177113
|
|
hypoglycemia |
J:177113
|
|
improved glucose tolerance |
J:177113
|
|
increased insulin sensitivity |
J:177113
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
hydronephrosis |
J:211179
|
|
normal
neoplasm |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
normal
homeostasis/metabolism phenotype |
J:177113
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
small kidney |
J:211179
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell proliferation |
J:98920
|
|
abnormal epidermal layer morphology |
J:98920
|
|
abnormal forestomach morphology |
J:98920
|
|
abnormal hair follicle morphology |
J:98920
|
|
abnormal intermediate gastric gland morphology |
J:98920
|
|
abnormal intestinal epithelium morphology |
J:98920
|
|
abnormal small intestine morphology |
J:98920
|
|
abnormal stomach epithelium morphology |
J:98920
|
|
abnormal stomach glandular epithelium morphology |
J:98920
|
|
abnormal stomach mucosa morphology |
J:98920
|
|
dehydration |
J:98920
|
|
increased skin tumor incidence |
J:98920
|
|
lethargy |
J:98920
|
|
premature death |
J:98920
|
|
spleen atrophy |
J:98920
|
|
stomach epithelial hyperplasia |
J:98920
|
|
thymus atrophy |
J:98920
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal intestine physiology |
J:199754
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:199754
|
|
increased cell proliferation |
J:199754
|
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
normal
mortality/aging |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1tm2(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased neutrophil cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
premature death |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm2(tetO-U2AF1)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
involves: 129S4/SvJae * C57BL/6
|
normal
hematopoietic system phenotype |
J:221403
|
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N
|
cardiac hypertrophy |
J:209629
|
|
decreased body size |
J:209629
|
|
embryonic lethality, incomplete penetrance |
J:209629
|
|
hydrocephaly |
J:209629
|
|
premature death |
J:209629
|
|
seizures |
J:209629
|
|
tremors |
J:209629
|
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6
|
abnormal mitochondrial crista morphology |
J:209629
|
|
abnormal mitochondrial morphology |
J:209629
|
|
abnormal mitochondrial physiology |
J:209629
|
|
abnormal myocardial fiber mitochondrial morphology |
J:209629
|
|
abnormal myocardial fiber morphology |
J:209629
|
|
abnormal sarcomere morphology |
J:209629
|
|
abnormal skeletal muscle fiber mitochondrial morphology |
J:209629
|
|
abnormal skeletal muscle morphology |
J:209629
|
|
abnormal Z line morphology |
J:209629
|
|
blood vessel congestion |
J:209629
|
|
brain vacuoles |
J:209629
|
|
cardiac fibrosis |
J:209629
|
|
decreased cardiac muscle contractility |
J:209629
|
|
decreased mitochondrial number |
J:209629
|
|
dilated cardiomyopathy |
J:209629
|
|
enlarged heart |
J:209629
|
|
increased cardiomyocyte apoptosis |
J:209629
|
|
increased skeletal muscle glycogen level |
J:209629
|
|
lethargy |
J:209629
|
|
neurodegeneration |
J:209629
|
|
premature death |
J:209629
|
|
respiratory distress |
J:209629
|
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
abnormal liver morphology |
J:210545
|
|
decreased circulating alanine transaminase level |
J:210545,
J:213764
|
|
decreased circulating cholesterol level |
J:213764
|
|
decreased circulating interleukin-6 level |
J:210545
|
|
decreased liver triglyceride level |
J:210545
|
|
decreased liver weight |
J:210545
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:210545
|
|
decreased susceptibility to injury |
J:213764
|
|
impaired glucose tolerance |
J:210545
|
|
increased bile salt level |
J:213764
|
|
increased circulating cholesterol level |
J:210545
|
|
increased circulating triglyceride level |
J:210545
|
|
increased liver weight |
J:213764
|
|
insulin resistance |
J:210545
|
|
liver inflammation |
J:210545
|
|
normal
liver/biliary system phenotype |
J:213764
|
|
normal
mortality/aging |
J:213764
|
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal skeleton morphology |
J:213764
|
|
ascites |
J:213764
|
|
enlarged spleen |
J:213764
|
|
lethargy |
J:213764
|
|
liver fibrosis |
J:213764
|
|
weight loss |
J:213764
|
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal forelimb morphology |
J:171191
|
|
abnormal hair follicle morphology |
J:171191
|
|
abnormal hindlimb morphology |
J:171191
|
|
decreased body size |
J:171191
|
|
delayed endochondral bone ossification |
J:171191
|
|
excessive hair |
J:171191
|
|
failure of endochondral bone ossification |
J:171191
|
|
fetal growth retardation |
J:171191
|
|
hydrops fetalis |
J:171191
|
|
increased leukemia incidence |
J:171191
|
|
increased lymphoma incidence |
J:171191
|
|
increased T cell derived lymphoma incidence |
J:171191
|
|
polydactyly |
J:171191
|
|
postnatal growth retardation |
J:171191
|
|
premature death |
J:171191
|
|
progressive hair loss |
J:171191
|
|
short snout |
J:171191
|
Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
decreased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
involves: 129S4/SvJae * C57BL/6
|
decreased neuronal stem cell self-renewal |
J:207231
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
decreased body size |
J:177113
|
|
impaired glucose tolerance |
J:177113
|
|
increased circulating glucose level |
J:177113
|
|
increased circulating insulin level |
J:177113
|
|
postnatal growth retardation |
J:177113
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Myf5tm1(cre)Mrc/Myf5+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
decreased body length |
J:199720
|
|
decreased body size |
J:199720
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/?
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
decreased primordial germ cell number |
J:196313
|
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:157298
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
involves: 129S4/SvJae * BALB/c * C57BL/6
|
increased lung tumor incidence |
J:214230
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
increased lung adenocarcinoma incidence |
J:214230
|
|
increased lung tumor incidence |
J:214230
|
|
premature death |
J:214230
|
|
respiratory distress |
J:214230
|
|
weight loss |
J:214230
|
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal hair follicle morphology |
J:171191
|
|
decreased body size |
J:171191
|
|
excessive hair |
J:171191
|
|
increased leukemia incidence |
J:171191
|
|
increased lymphoma incidence |
J:171191
|
|
increased T cell derived lymphoma incidence |
J:171191
|
|
postnatal growth retardation |
J:171191
|
|
premature death |
J:171191
|
|
progressive hair loss |
J:171191
|
|
short snout |
J:171191
|
Col1a1tm4(tetO-Jun/Fosl2)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
decreased liver triglyceride level |
J:210545
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:210545
|
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
increased lung tumor incidence |
J:214230
|
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
cachexia |
J:171191
|
|
increased lung adenoma incidence |
J:171191
|
|
increased tumor incidence |
J:171191
|
|
premature death |
J:171191
|
|
respiratory distress |
J:171191
|
Col1a1tm5(tetO-Jun/Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N
|
abnormal liver morphology |
J:210545
|
|
premature death |
J:210545
|
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:163322
|
|
abnormal erythrocyte morphology |
J:163322
|
|
abnormal leukocyte morphology |
J:163322
|
|
abnormal myelopoiesis |
J:163322
|
|
decreased common myeloid progenitor cell number |
J:163322
|
|
decreased lymphocyte cell number |
J:163322
|
|
decreased neutrophil cell number |
J:163322
|
|
enlarged spleen |
J:163322
|
|
increased bone marrow cell number |
J:163322
|
|
increased erythrocyte cell number |
J:163322
|
|
increased hematocrit |
J:163322
|
|
increased hematopoietic stem cell number |
J:163322
|
|
increased leukemia incidence |
J:163322
|
|
increased leukocyte cell number |
J:163322
|
|
increased liver weight |
J:163322
|
|
increased mean corpuscular volume |
J:163322
|
|
increased spleen weight |
J:163322
|
|
increased susceptibility to induced morbidity/mortality |
J:163322
|
|
spleen hyperplasia |
J:163322
|
|
thrombocytopenia |
J:163322
|
Col1a1tm8(CAG-BDNF)Jae/Col1a1+
Mecp2tm1.1Jae/Y
Tg(Camk2a-cre)93Kln/0
involves: 129S4/SvJae * C57BL/6 * CBA/J
|
abnormal action potential |
J:106973
|
|
normal
behavior/neurological phenotype |
J:106973
|
|
decreased brain weight |
J:106973
|
|
premature death |
J:106973
|
Col1a1tm8(CAG-BDNF)Jae/Col1a1tm8(CAG-BDNF)Jae
Tg(Sim1-cre)1Lowl/0
involves: 129S4/SvJae * C57BL/6 * FVB
|
abnormal hypothalamus physiology |
J:179918
|
|
normal
homeostasis/metabolism phenotype |
J:179918
|
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
abnormal cell cycle |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
abnormal cell cycle |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
chimera involves: 129S4/SvJae * C57BL/6
|
infertility |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
early cellular replicative senescence |
J:171348
|
|
neonatal lethality, complete penetrance |
J:171348
|
|
no abnormal phenotype detected |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:171348
|
|
abnormal small intestinal crypt cell proliferation |
J:171348
|
|
decreased erythroid progenitor cell number |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
early cellular replicative senescence |
J:171348
|
|
neonatal lethality, complete penetrance |
J:171348
|
|
no abnormal phenotype detected |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:171348
|
|
abnormal small intestinal crypt cell proliferation |
J:171348
|
|
decreased erythroid progenitor cell number |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle checkpoint function |
J:231166
|
|
abnormal mitosis |
J:231166
|
|
abnormal mitotic spindle morphology |
J:231166
|
|
aneuploidy |
J:231166
|
|
chromosomal instability |
J:231166
|
|
increased lung tumor incidence |
J:231166
|
|
increased tumor incidence |
J:231166
|
Col1a1tm13(tetO-Nup88)Jvd/Col1a1+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle checkpoint function |
J:231166
|
|
abnormal mitosis |
J:231166
|
|
abnormal mitotic spindle morphology |
J:231166
|
|
aneuploidy |
J:231166
|
|
chromosomal instability |
J:231166
|
|
increased lung tumor incidence |
J:231166
|
|
increased tumor incidence |
J:231166
|
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
normal
digestive/alimentary phenotype |
J:222595
|
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Excel File
Analysis Tools